bioMerieux (OTCMKTS:BMXMF) Receives Average Rating of “Reduce” from Brokerages

bioMerieux (OTCMKTS:BMXMF) has received a consensus rating of “Reduce” from the six ratings firms that are covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation and four have issued a hold recommendation on the company.

A number of brokerages have recently commented on BMXMF. UBS Group downgraded shares of bioMerieux from a “buy” rating to a “neutral” rating in a research report on Monday, June 1st. Morgan Stanley cut shares of bioMerieux from an “overweight” rating to an “underweight” rating in a report on Tuesday, June 23rd. Zacks Research downgraded shares of bioMerieux from a “hold” rating to a “strong sell” rating in a research note on Friday, July 31st. Piper Sandler initiated coverage on bioMerieux in a report on Thursday, June 11th. They set a “neutral” rating for the company. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of bioMerieux in a research note on Wednesday, June 17th.

bioMerieux Price Performance

OTCMKTS:BMXMF opened at $78.99 on Wednesday. bioMerieux has a 1-year low of $77.00 and a 1-year high of $152.00. The firm has a fifty day simple moving average of $79.97 and a 200 day simple moving average of $95.49. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.39 and a quick ratio of 1.48.

bioMerieux Company Profile

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.